🇺🇸 FDA
Patent

US 11021545

Multimodal cancer therapy comprising chimeric viral/nonviral nanoparticles and anticancer agents

granted A61KA61K31/506A61K31/7105

Quick answer

US patent 11021545 (Multimodal cancer therapy comprising chimeric viral/nonviral nanoparticles and anticancer agents) held by The Regents of the University of California expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/506, A61K31/7105, A61K45/06